2020 Pediatric Rheumatology Symposium

April 29-May 2, 2020

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d [e] f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 098

Early Treatment with Anakinra in Systemic Juvenile Idiopathic Arthritis
Abstract Number: 177

Educational Outcomes in a Young-Adult Cohort of Patients with Childhood Onset Systemic Lupus Erythematosus (SLE)
Abstract Number: 009

Emapalumab (Anti-Interferon-Gamma Monoclonal Antibody) in Patients with Macrophage Activation Syndrome (MAS) Complicating Systemic Juvenile Idiopathic Arthritis (sJIA)
Abstract Number: 074

Establishment of a Registry for Juvenile Idiopathic Arthritis (JIA) Patients in South Australia (SA): Focus on Patient Reported Outcome Measures (PROMs) and Experiences (PREMs)
Abstract Number: 121

Evaluating the Relationship Between Juvenile Idiopathic Arthritis Disease Activity and Uveitis Activity: A Retrospective Analysis
Abstract Number: 113

Evaluation of B-cell Depletion with Rituximab and IVIG Concurrent Treatment in Pediatric Autoimmune Brain Disease
Abstract Number: 134

Evaluation of Self-report Screening Measures in the Detection of Depressive and Anxiety Disorders Among Children and Adolescents with Systemic Lupus Erythematosus
Abstract Number: 193

Examining Social Loafing and the Free-Rider Effect in Transition Readiness Among Youth with jSLE
Abstract Number: 168

Examining the Role of IFN-I and Langerhans Cell ADAM17 in Lupus Photosensitivity
Abstract Number: 031

Exome Sequencing for Early Pediatric Systemic Lupus Erythematosus: Standard of Care in 2020?
Abstract Number: 010

Experience with and Management of HLH-like Toxicities Following Chimeric Antigen Receptor T-Cell Therapy for Treatment of Relapsed/Refractory Pre-B ALL

Jump to: View All • a b c d [e] f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].